

TN-1334

Sensitive and Reproducible Quantification of N-Nitroso Propranolol in a Propranolol Drug Substance and Product

Pankaj Partani¹, Sandeep Choudhary, PhD¹, Preeti Bharatiya¹, Upendra Gunta¹, Ranjith Kumar Ponnamaneni¹, Manoj Pillai, PhD¹, Rahul Baghla², Eshani Nandita, PhD², and Bryan Tackett, PhD³

¹SCIEX Lab, Hitech Defence and Aerospace Park Industrial Area, Mahadeva Kodigehalli, Hobli, Jala Taluka, Bengaluru 562149 India

²AB Sciex LLC, 500 Old Connecticut Path, Framingham, MA 01701, USA

³Phenomenex Inc., 411 Madrid Ave., Torrance, CA 90501, USA

Introduction

Propranolol, a synthetic amino alcohol, is a competitive nonselective β -adrenoreceptor antagonist extensively used to treat hypertension, angina pectoris, and other cardiac diseases. β -adrenergic blocking drugs such as Propranolol, Atenolol, Metoprolol, Nadolol, Oxprenolol, and Sotalol contain amine groups. As a result, these drugs react with Sodium Nitrite in a Hydrochloric Acid solution to produce N-Nitrosamines.

Per regulatory guidance, Nitrosamine impurity limits are defined and must be controlled in drugs due to their carcinogenicity. Previous studies have revealed that the N-Nitroso Propranolol impurity is approximately 16-fold more carcinogenic than the N-Nitroso Dimethylamine (NDMA) impurity. Therefore, there is an important need to develop assays for the sensitive detection and quantification of the N-Nitroso Propranolol impurity in drug substance and drug products.

This technical note describes the quantification of the N-Nitroso Propranolol impurity in a Propranolol drug substance and product using a Kinetex 2.6 μ m Biphenyl HPLC column and a SCIEX[®] QTRAP[®] 6500+ system. A lower limit of quantification (LLOQ) of 0.01 ng/mL was achieved for N-Nitroso Propranolol with high reproducibility and accuracy (Figure 1). In addition, linearity was achieved between 0.01 ng/mL and 10.00 ng/mL, providing a linear dynamic range (LDR) of 3 orders of magnitude.

Sample Preparation

Standard preparation: A 1 mg/mL N-Nitroso Propranolol solution was prepared in Methanol. The stock solution was diluted with Acetonitrile / Water (80:20, v/v) to prepare calibration standards at concentrations ranging from 0.005 to 10 ng/mL that were stored under refrigerated conditions.

Drug substance: Propranolol was weighed and diluted to a final concentration of 1 mg/mL in Acetonitrile / Water (80:20, v/v). The sample was shaken for 20 minutes using a mechanical wrist action shaker. After extraction, the sample was centrifuged for 10 minutes at 4000 rpm. The supernatant was collected and filtered using a 0.22 μ m PVDF syringe filter. The filtered solution was transferred into an HPLC vial for analysis.

Drug product: The drug product was crushed and weighed. A 1 mg/mL solution of the drug product with respect to the active pharmaceutical ingredient (API) was prepared using Acetonitrile / Water (80:20, v/v). The solution was vortexed for 2 minutes and shaken for 30 minutes using a mechanical wrist action shaker. After extraction, the sample was centrifuged for 10 minutes at 4000 rpm. The supernatant was collected and filtered using a 0.22 μ m PVDF syringe filter. The filtered solution was transferred into an HPLC vial for analysis.

LC Conditions

Column: Kinetex™ 2.6 μ m Biphenyl
Dimensions: 150 x 3.0 mm
Part No.: [00F-4622-YO](#)
Mobile Phase: A: 1 mM Ammonium Formate with 0.1 % Formic Acid in Water
 B: 0.1 % Formic Acid in Acetonitrile

Gradient:	Time (min)	%B
	0.00	35
	3.00	35
	5.00	55
	6.00	75
	8.00	75
	8.10	95
	10.0	95
	10.1	35
	14.0	35

Flow Rate: 0.4 mL/min
Injection Volume: 15 μ L
Temperature: 40 °C
LC System: SCIEX ExionLC™
Detection: MRM
Detector: SCIEX QTRAP 6500+

MRM Conditions

Polarity: Positive
Source Temperature: 450 °C
GS1: 60 psi
GS2: 60 psi
CUR: 40 psi
CAD: 10
IS: 5500 V

MRM Transitions and Parameters

Analyte	Q1 (m/z)	Q3 (m/z)	Dwell (sec)	DP (V)	EP (V)	CE (V)	CXP (V)
N-Nitroso Propranolol-1	289.1	259.1	150	50	10	8	14
N-Nitroso Propranolol-2	289.1	72.1	150	50	10	15	15

Note: N-Nitroso Propranolol-1 was used as a quantifier transition and N-Nitroso Propranolol-2 was used as a qualifier transition.



Results and Discussion

The Kinetex™ 2.6 µm Biphenyl LC column was selected for separation, as it provided high separation power. Under the optimal LC-MS/MS conditions, the N-Nitroso Propranolol impurity eluted at a retention time of 7.30 minutes. Matrix interferences were not observed in the diluent or control samples, demonstrating the selectivity and specificity of the assay. A limit of detection (LOD) of 0.005 ng/mL and LLOQ of 0.010 ng/mL for the N-Nitroso Propranolol impurity were achieved. The representative chromatograms for the matrix blank and sample at the LOD, LLOQ, and specification limit of the sample are shown in **Figure 2**. The signal-to-noise (S/N) ratios observed at the LOD and LLOQ levels were >10 and >20, respectively.

The upper limit of quantification (ULOQ) was selected based on the highest levels of analytes expected to be observed and is not a reflection of system capability. The calibration curve generated for the concentrations tested is shown in **Figure 3** with an overlay of the linearities for both the quantifier and qualifier transition responses. Linearity was demonstrated over a concentration range of 0.01 ng/mL to 10.00 ng/mL. A correlation coefficient (r^2) of >0.99 was achieved for responses from both transitions.

Accuracy was expressed as percentage deviation from the nominal value at each respective concentration level. The precision of the assay was measured by the percent coefficient of variation (%CV) at each of the concentrations. Accuracy and %CV were determined by analyzing 6

replicates of the samples at the LLOQ and specification limit in a single analytical run. As shown in **Table 1**, the %CV values at the LLOQ and specification limit were 6.74 % and 3.59 %, respectively. Accuracy ranged from 96 % to 115 % at the LLOQ and 107 % to 116 % at the specification limit, averaging 105 % and 110 %, respectively. Overall, these data confirm the accuracy and high reproducibility of the method for quantifying N-Nitroso Propranolol (**Table 1**).

Two MRM transitions were used to provide an additional level of specificity for N-Nitroso Propranolol quantification (**Table 2**). The ion ratios for the N-Nitroso Propranolol spike samples are similar to the ratios observed in the standard solution, indicating that under the optimized LC-MS/MS conditions, the interferences at the retention time of N-Nitroso Propranolol are negligible. Representative chromatograms shown in **Figure 4** highlight the ion ratio lines with a tolerance of ± 30 %. Recovery was evaluated in 3 matrices, including the placebo, API, and drug product. Recovery was assessed at 0.01 ng/mL, 0.03 ng/mL, 1 ng/mL, and 5 ng/mL for the placebo and API samples. Since N-Nitroso Propranolol was detected in the drug product at 0.185 ng/mL, the recovery analysis was performed at 1 ng/mL and 5 ng/mL. In the case of the placebo sample, no area response was observed at the retention time of N-Nitroso propranolol. **Table 2** summarizes the recoveries observed for all evaluated matrix samples. Recoveries between 85 % and 111 % were achieved, indicating that the extraction workflow achieved good recovery for N-Nitroso Propranolol in both the drug substance and drug product.

Figure 1. Representative Chromatograms of the Quantifier and Qualifier Transitions for N-Nitroso Propranolol in the Solvent Blank and at the LLOQ.




Figure 2. Chromatograms of the Matrix Blank and Sample at the LOD, LLOQ, and Specification Limit.




Figure 3. Calibration Curves were Generated using the Quantifier (Blue) and the Qualifier (Pink) Transition Responses.




Table 1. Accuracy and %CV at 3 Concentration Levels.


Replicate No.	LLOQ (0.01 ng/mL)	0.03 ng/mL	Specification Limit (1 ng/mL)
1	0.011	0.029	1.156
2	0.010	0.031	1.096
3	0.010	0.030	1.084
4	0.011	0.031	1.070
5	0.011	0.032	1.082
6	0.010	0.031	1.160
Mean	0.011	0.031	1.108
SD (%)	0.001	0.001	0.040
%CV	6.74	3.30	3.59
% Accuracy	105	103	111

Table 2. Recovery Results from the Standard Solutions and Spiked Samples.

Sample Type	Concentration (ng/mL)	Mean Area Response in Control Samples (Mean ± SD)	Mean Area Response in Standard Solutions (Mean ± SD)	Mean Area Response in Spiked Samples (Mean ± SD)	Recovery (%)
Placebo	0.01	Not Detected	9979 ± 642	10622 ± 1155	106
	0.03		28446 ± 924	29886 ± 886	105
	1		1005374 ± 36034	934359 ± 6170	92.9
	5		4878501 ± 221584	4858043 ± 37729	99.6
API	0.01	11248 ± 698.7	9979 ± 642	19525 ± 863	91.9
	0.03		28446 ± 924	36689 ± 420	92.4
	1		1005374 ± 36034	945876 ± 5629	93.0
	5		4878501 ± 221584	4651926 ± 28735	95.1
Drug Product	1	168938 ± 8961.1	1005374 ± 36034	1008797 ± 8748	85.9
	5		4878501 ± 221584	4669906 ± 45067	92.5



Figure 4. Chromatograms of N-Nitroso Propranolol for Standard Solutions and Spiked Samples.



Conclusions

Low-level quantification of the N-Nitroso Propranolol impurity in Propranolol drug product was achieved using a Kinetex™ 2.6 µm Biphenyl HPLC column in conjunction with the SCIEX® QTRAP® 6500+ system. Accurate and highly reproducible quantification of N-Nitroso Propranolol was demonstrated. Linearity was achieved between 0.01 to 10 ng/mL, generating an LDR of 3 orders of magnitude. The method demonstrated a simple sample preparation workflow with high recovery. The recovery was evaluated in placebo, API, and drug product matrices.

Kinetex Ordering Information

Phases	2.6 µm Midbore™ Columns (mm)			SecurityGuard™ ULTRA Cartridges (mm)‡		
	30 x 3.0	50 x 3.0	75 x 3.0	100 x 3.0	150 x 3.0	3/pk
EVO C18	00A-4725-Y0	00B-4725-Y0	—	00D-4725-Y0	00F-4725-Y0	AJ0-9297
PS C18	00A-4780-Y0	00B-4780-Y0	—	00D-4780-Y0	00F-4780-Y0	AJ0-8950
Polar C18	—	00B-4759-Y0	—	00D-4759-Y0	00F-4759-Y0	AJ0-9531
Biphenyl	—	00B-4622-Y0	—	00D-4622-Y0	00F-4622-Y0	AJ0-9208
XB-C18	00A-4496-Y0	00B-4496-Y0	00C-4496-Y0	00D-4496-Y0	00F-4496-Y0	AJ0-8775
C18	00A-4462-Y0	00B-4462-Y0	00C-4462-Y0	00D-4462-Y0	00F-4462-Y0	AJ0-8775
C8	00A-4497-Y0	00B-4497-Y0	00C-4497-Y0	00D-4497-Y0	00F-4497-Y0	AJ0-8777
HILIC	00A-4461-Y0	—	—	00D-4461-Y0	00F-4461-Y0	AJ0-8779
Phenyl-Hexyl	—	00B-4495-Y0	—	00D-4495-Y0	00F-4495-Y0	AJ0-8781
F5	—	00B-4723-Y0	—	00D-4723-Y0	00F-4723-Y0	AJ0-9321

for 3.0 mm ID

‡SecurityGuard ULTRA Cartridges require holder, Part No.: [AJ0-9000](#)



Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/Chat.

Australia

t: +61 (0)2-9428-6444
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077
cz-info@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

Hong Kong

t: +852 6012 8162
hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Indonesia

t: +62 21 5019 9707
indoinfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Japan

t: +81 (0) 120-149-262
jpinfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: +48 22 104 21 72
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: +65 6559 4364
sginfo@phenomenex.com

Slovakia

t: +420 272 017 077
sk-info@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287
thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
www.phenomenex.com/chat

**🌐 All other countries/regions
Corporate Office USA**

t: +1 (310) 212-0555
www.phenomenex.com/chat

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

BE-HAPPY™
GUARANTEE

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/phx-terms-and-conditions-of-sale.

Trademarks

Kinetex, MidBore, SecurityGuard, and BE-HAPPY are trademarks of Phenomenex. SCIEX and QTRAP are registered trademarks and ExionLC is a trademark of AB SCIEX Pte. Ltd.

Disclaimer

Comparative separations may not be representative of all applications.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2023 Phenomenex, Inc. All rights reserved.

